Tag: MARRS
Late-breaking MARRS trial data reveal 61% first-pass effect rate with Perfuze’s...
Perfuze has announced the presentation of positive preliminary results from its pivotal MARRS investigational device exemption (IDE) clinical trial at the Society for NeuroInterventional...
Perfuze completes enrolment in pivotal US study, appoints new executive vice...
Perfuze has announced two “significant milestones” in its mission to improve stroke care: the completion of patient enrolment in its US pivotal investigational device...
Perfuze enrols first stroke patient in MARRS pivotal trial of Millipede...
Perfuze has announced commencement of enrolment in its pivotal MARRS study—a multicentre trial set to evaluate the performance of aspiration thrombectomy with the company’s...
